Celcuity Block Pam. Unlock Tomorrow
Celcuity is a clinical-stage biotechnology company developing molecularly targeted therapies for solid tumor cancers driven by PI3K pathway dysregulation. Its lead candidate, gedatolisib, is a pan-PI3K/mTOR inhibitor being evaluated in Phase 3 trials for HR+/HER2- advanced breast cancer and has received an FDA NDA acceptance. The company also develops companion diagnostics to identify patients most likely to benefit from its precision oncology therapies.
Tech & App Stack is available on paid plans
Upgrade to Silver or higher to reveal the full technology and app stack for any company.
View pricingCreate a free account to see funding visualizations and detailed round data.
Create Free AccountAug 2025
Aug 2025
May 2017
Feb 2016
Mar 2014
Create a free account to see which investors have funded this company.
Create Free Account
Provides comprehensive molecular profiling and AI-driven precision oncology services for physicia...
Developer of engineered cells as medicines to treat diseases by repairing or replacing cells for ...
China's leading mRNA biotech company developing therapeutics for cancer and infectious diseases.
Late-stage biopharma using single-molecule tracking, AI, and engineering to discover and develop ...
Biopharmaceutical company developing and commercializing RNAi therapeutics to treat genetically d...
Clinical-stage programmable cell therapy company developing engineered T-cell therapies for solid...
